All News

Dr. Vishal Patel explains what Libtayo’s FDA approval means for patients with high-risk cutaneous squamous cell carcinoma.

As a survivor, I see pink ribbons everywhere, but what we really need is more research, better treatments, and real change for those living with cancer.

Dr. Patrick J. Hensley explains non-muscle invasive bladder cancer, bladder-preserving treatments, trial eligibility, novel therapies and research priorities for patients.

The FDA granted fast track designation to VT3989 for unresectable malignant nonpleural or pleural mesotherlioma.

Dr. Ravi Munver highlights how minimally invasive treatment has improved recovery and quality, improving outcomes for patients with kidney cancer

Remote monitoring has been found to be associated with improved postsurgical recovery for patients with cancer.

Dr. Sheldon Marc Feldman explores Reiki’s potential to reduce stress and anxiety for patients undergoing breast cancer surgery at Montefiore Einstein.

The FDA has approved Libtayo for the postsurgical treatment of adults with cutaneous squamous cell carcinoma.

At the age of 34, I received the biggest news of my life, which was my diagnosis with colon cancer. I remember that day like it was yesterday.

The FDA granted fast track status to UB-VV111 for patients with relapsed or refractory large B-cell lymphoma or chronic lymphocytic leukemia.

Dr. Evan Garfein said 3D printing and tissue-engineered implants may make breast reconstruction safer, more personalized and less physically taxing.

It’s October, and social media sites are full of vendors selling merchandise featuring pink ribbons. But here's the thing...

Dr. Nicolas Girard discussed the current treatment options for patients with EGFR-mutant lung cancer, including emerging combination regimens.

After Barbara Tatham’s passing from metastatic sarcoma, her sister and friend completed her memoir, highlighting caregiving, resilience and family support.

As a Lynch syndrome previvor, I felt that the film “Love, Danielle” struck a deeply personal chord.

As we approach Lung Cancer Awareness Month this November, it’s important to reflect on the latest developments and insights in lung cancer research.

The FDA granted orphan drug designation to cintredekin besudotox for glioblastoma, supporting further research for this aggressive brain cancer.

Dr. Fred Hirsch highlighted how knowledge of the molecular characteristics of non-small cell lung cancer enhances understanding of the disease.

In locally recurrent inoperable or metastatic TNBC, Datroway resulted in improvement in overall survival and progression-free survival.

In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in survival.

October is Breast Cancer Awareness Month, and CURE is here to address some of the most common questions patients have after a breast cancer diagnosis.

My cancer journey began with a surgical oncologist who extracted my one-inch pancreatic tumor, taking with it the top third of my pancreas.

The New Jersey retreat is free for women during and two years after cancer treatment.

A biologics license application for PVEK has been submitted to the FDA for blastic plasmacytoid dendritic cell neoplasm, a rare blood cancer.

CAR-T cell therapy has cured some children with blood cancers and is being studied in solid tumors, where responses differ due to how these cancers grow.

As we kick off Breast Cancer Awareness Month, it’s an opportune time to reflect on some of the most important breast cancer stories shared last month.

September’s top gastrointestinal cancer news covered long-term Gleevec results for GIST, a pancreatic cancer vaccine and FDA designations.

The author and advocate, facing leukemia for the third time in 15 years, sat down for an interview with CURE.